BNT162b2 Versus mRNA‐1273 Vaccines: Comparative Analysis of Long‐Term Protection Against SARS‐CoV‐2 Infection and Severe COVID‐19 in Qatar
Influenza and Other Respiratory Viruses · 2024
DOI: 10.1111/irv.13357 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Influenza and Other Respiratory Viruses, 2024. Verfasst von Hiam Chemaitelly und 21 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar. Hauptthemen laut MEDLINE: BNT162 Vaccine, COVID-19, 2019-nCoV Vaccine mRNA-1273, SARS-CoV-2. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Weill Cornell Medicine-Qatar, Ministry of Public Health, Hamad Medical Corporation.
Abstract (Originalsprache)
Background
This study provides a head‐to‐head comparison of the protection provided by the BNT162b2 and mRNA‐1273 vaccines against SARS‐CoV‐2 infection and against severe COVID‐19, covering primary series and third dose/booster vaccinations over up to 3 years of follow‐up, both before and after the emergence of the omicron variant.
Methods
Two national, matched, retrospective cohort studies were conducted on Qatar's vaccinated population from December 16, 2020, to February 18, 2024. Subgroup analyses by pre‐vaccination SARS‐CoV‐2 infection history, as well as sensitivity analyses, were also conducted.
Results
The adjusted hazard ratio (AHR) comparing infection incidence in those vaccinated with BNT162b2 versus mRNA‐1273 was 1.03 (95% CI: 1.02–1.05) after the primary series and 1.11 (95% CI: 1.09–1.13) after the third (booster) dose. The corresponding AHRs for any severe, critical, or fatal COVID‐19 were 1.31 (95% CI: 0.81–2.11) and 1.00 (95% CI: 0.20–4.94), respectively. Subgroup analyses by prior infection status hinted at a dose‐dependent immune imprinting effect, where a combination of two types of immunity, pre‐omicron and omicron, offered greater protection against infection than one type alone, with this effect being amplified by the higher antigen dose of mRNA‐1273 compared to BNT162b2. Sensitivity analyses confirmed the study findings.
Conclusions
BNT162b2 provided slightly less protection against infection than mRNA‐1273 following both primary series and booster vaccinations while offering comparable protection against severe COVID‐19 outcomes. The findings suggested that the vaccine antigen dose in interaction with infection history may determine the extent of immune protection against infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar.
- World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation - E…
- Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, New York, USA.
- Mathematics Program, Department of Mathematics and Statistics, College of Arts and Sciences, Qatar University, Doha, Qatar.
- Department of Biomedical Science, College of Health Sciences, QU Health, Qatar University, Doha, Qatar.
- Hamad Medical Corporation, Doha, Qatar.
ORCID-Profile: Hiam Chemaitelly, Houssein H Ayoub, Mohammad R Hasan, Gheyath K Nasrallah, Laith J Abu-Raddad
Förderung
- Weill Cornell Medicine-Qatar
- Ministry of Public Health
- Hamad Medical Corporation
- Sidra Medicine
- Qatar Genome Programme
- Qatar University
- Weill Cornell Medicine - Qatar
Zitieren
APA
Chemaitelly, H., Ayoub, H. H., Coyle, P., Tang, P., Hasan, M. R., Yassine, H. M., Al Thani, A. A., Al-Kanaani, Z., Al-Kuwari, E., Jeremijenko, A., Kaleeckal, A. H., Latif, A. N., Shaik, R. M., Abdul-Rahim, H. F., Nasrallah, G. K., Al-Kuwari, M. G., Butt, A. A., Al-Romaihi, H. E., Al-Thani, M. H., …, & Abu-Raddad, L. J. (2024). BNT162b2 Versus mRNA‐1273 Vaccines: Comparative Analysis of Long‐Term Protection Against SARS‐CoV‐2 Infection and Severe COVID‐19 in Qatar. Influenza and Other Respiratory Viruses. https://doi.org/10.1111/irv.13357
Vancouver
Chemaitelly H, Ayoub HH, Coyle P, Tang P, Hasan MR, Yassine HM, et al. BNT162b2 Versus mRNA‐1273 Vaccines: Comparative Analysis of Long‐Term Protection Against SARS‐CoV‐2 Infection and Severe COVID‐19 in Qatar. Influenza and Other Respiratory Viruses. 2024. doi:10.1111/irv.13357
BibTeX
@article{Chemaitelly2024,
author = {Chemaitelly, Hiam and Ayoub, Houssein H and Coyle, Peter and Tang, Patrick and Hasan, Mohammad R and Yassine, Hadi M and Al Thani, Asmaa A and Al-Kanaani, Zaina and Al-Kuwari, Einas and Jeremijenko, Andrew and Kaleeckal, Anvar Hassan and Latif, Ali Nizar and Shaik, Riyazuddin Mohammad and Abdul-Rahim, Hanan F and Nasrallah, Gheyath K and Al-Kuwari, Mohamed Ghaith and Butt, Adeel A and Al-Romaihi, Hamad Eid and Al-Thani, Mohamed H and Al-Khal, Abdullatif and Bertollini, Roberto and Abu-Raddad, Laith J},
title = {BNT162b2 Versus mRNA‐1273 Vaccines: Comparative Analysis of Long‐Term Protection Against SARS‐CoV‐2 Infection and Severe COVID‐19 in Qatar},
journal = {Influenza and Other Respiratory Viruses},
year = {2024},
doi = {10.1111/irv.13357}
}
EUVIMED